I love the last statement the best.. "After all he has

New Post Public Reply Private Reply Replies (3) Message Board
longboardsurfer90210 intlinfusion #19524
I love the last statement the best.. "After all he has raised enough capital to get us where we are and built solid enough connections for people to trust him enough to sell him these assets."

The capital he has raised is exactly why we are where we are at. Trust? Companies were trying to get these assets off their hands as quick as possible, just like I would imagine we are trying to do now.

Most all of you know that I have been here since beginning of 2012 and had all the confidence in the world in the company's vision and strategy. When Gerald put out his blogs, I had no reason to doubt him and made my investing decision based on his updates, always hoping that he was a man of integrity. Well, as of recent, I question that integrity. I question what he meant when he spoke of "shareholder value". I question what he meant when he spoke of "institutional investors" wanting to get in. Where did they go? I question his rush to up list. I question all of his "NDA's". Did they really ever exist or were those total lies? I question all of the "Great interest in KOL's". Besides the interest in ESS from the burn community, what about everything else? Tax credit? What happened to that? Where are all of the grants that we hired a paid employee to find for us? Other than Dr. Lowe (and his contract expiring explanation) , what is up with talent leaving AMBS? I could just continue on and on if I had the motivation to go back in history and comments from Gerald and point out that his statements either lacked evidence completely and would just be considered hearsay or would fall under the classification of delusion.

There are those that will point out the things "he has accomplished", but as a shareholder, I could care less that he has all these assets that it seems BP's and these supposed "institutional investors" are not interested in, and that in return we are sitting with 90-95 % losses over the last three years. Average down? What if you didn't have the money to average down and made your initial investment decision based on the info coming from management. Has a single milestone been met? We have jumped around, trying to find that magical asset that will generate non dilutive funding, but here we are about to be reversed split into oblivion. My shares are worth nothing at this point and will be worth less once that happens.

I understand those that have thrown in the towel and feel as if Gerald does not "deserve" to continue to screw (misstate the facts and continually over promise) over any other/future investors. His lack of communication and outright lies (oops I mean "overstatements" in his previous blogs reeks of indifference to shareholders and boarder on deceptive communication.

At this point, it would be ridiculous to sell my shares. What would be the point? However, as of today, based on history, I could care less and actually hope for his demise. I can only judge a man by his actions. His actions have spoken WAY louder than his words. By not communicating what has been going on with the company, getting into bed with financiers that did not have AMBS's interest at heart, thereby risking our investment and destroying the share price, as he has done , is not excusable. I would have been able to forgive had he been transparent all along concerning his mistakes and how he planned to correct them, but leaving us all just wondering (take a look at all the posts the last few months with everyone "speculating" about what "must be going on". I spend the last nights reviewing posts from others on the board and we are all clueless. Clueless is not a good thing in the market. Go back and read the chairman's blogs. If there was ever a pumper, it was Gerald.

As I stated on the private board (which got me kicked off) I would exit this stock at break even just based on my standards of integrity, which I feel this company has sorely lacked. I am almost positive I will never see break even.

Sorry, but just had to vent. Been sitting here reading everyone's posts about what they think will happen and resigning to the fact that they have no choice but to vote in the additional shares as their only chance of ever getting their money back. What kind of position is that? Allow a irresponsible and uncommunicative CEO, cart blanche to save your own asses? At some point in time, unless he comes out and apologizes to shareholders for his mismanagement and lousy "financial engineering" of our hard earned money, I say, end the madness. I made a bad investment decision, am down over 90% and don't really care about the money as much as I care about not allowing an imbecile to continue on diluting us into oblivion after mentioning at one time that a "reverse split might not be necessary" and that he would only RS ONLY "into strength". It pains me to have to write this and I suspect that there are many others on this board that would echo my sentiment, but are afraid to share for being accused of being a basher or a "short" with an agenda. That sucks to!!! Here's to hoping we all become rich.....lol Most likely not with this investment.....at least from my perspective today.


Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 199

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 150

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading

Top 5 Most Recently Viewed Articles

Japan's Economic Outlook Dims as Export Weakness Persists

Updated Category News Views 189

Japan's Revised Economic Growth Forecast Recently, Japan's government announced a downward revision of its GDP growth forecast for the current fiscal year. This adjustment is significant as it reflects the ongoing struggles within the economy, particularly in light of weaker export performance that is hindering a fragile recovery. Details on the Growth Projection The...

Continue Reading
The Importance of Employee Recognition in the Workplace

Updated Category News Views 254

The Importance of Employee Recognition in the Workplace Gratitude is a key theme during Thanksgiving, but in the workplace, recognition for employee contributions plays an equally significant role throughout the year. As companies strive to enhance their workplace culture, the value of recognizing employees cannot be overstated. Understanding Employer Perspectives A...

Continue Reading
Class Action Alert for Shareholders of Orthofix Medical

Updated Category News Views 196

Class Action Lawsuit Overview In the current landscape of securities litigation, investors in Orthofix Medical, Inc. have a critical opportunity to engage with a class action lawsuit that addresses significant issues of corporate governance and transparency. This legal action has arisen following severe corporate management changes that have caused share price...

Continue Reading
Understanding Recent Trends in Lowe's Short Interest

Updated Category News Views 107

Understanding Lowe's Companies' Short Interest Lowe's Companies (NYSE: LOW) has seen its short percent of float decrease by 12.78% since the last report. Currently, there are approximately 6.55 million shares sold short, which constitutes 1.16% of all shares available for trading. Given the current trading volume, it would take traders about 2.91 days to cover their short...

Continue Reading
YD Bio Limited and EG Biomed Enhance Clinical Testing with CAP Accreditation

Updated Category News Views 151

Transformative Advancements in Clinical Testing by YD Bio Limited YD Bio Limited, a pioneering biotechnology company known for its advancements in DNA methylation-based cancer detection, recently celebrated a significant milestone through its collaboration with EG Biomed US Inc. This partnership has propelled forward the capabilities of clinical testing, particularly in...

Continue Reading